GI Oncology

From the Journals

Consider adding chemotherapy after GI surgery

Average survival rates at 3 years after surgery were 40 months for those who received adjuvant chemotherapy vs. 34 months for those who did not....

News

FDA approves nivolumab for HCC patients

Approval of nivolumab for HCC was based on tumor response rate and durability of response from the phase 1/2 Checkmate 040 trial.

News

FDA approves biosimilar to bevacizumab

Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.

Pages